Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: The Wuhan Municipal Health Commission said seven other people were in critical condition among a total of 41 who were suffering from pneumonia caused by a “preliminarily determined new type of coronavirus” as of Friday. That was down from the earlier figure of 59. The others were in stable condition and at least two had been released from a hospital. The patient who died was identified as a 61-year-old man who had been hospitalized after suffering shortness of breath and severe pneumonia. The commission said the man, who died Thursday, also suffered from abdominal tumors and chronic liver disease and had been a frequent customer at a food market on Wuhan’s outskirts linked to the majority of cases. China says the cause of the Wuhan outbreak remains unknown, but has sought to quash speculation that it could be a reappearance of the SARS epidemic, which killed hundreds in 2002 and 2003. Coronaviruses are a large family of viruses, some of which cause the common cold. Others found in bats, camels and other animals have evolved into more severe illnesses. Common symptoms include a runny nose, headache, cough and fever. Shortness of breath, chills and body aches are associated with more dangerous kinds of coronaviruses, according to the U.S. Centers for Disease Control and Prevention. China’s transport ministry says it plans additional measures to disinfect trains, planes and buses and prevent transmission of diseases during the 40-day travel rush centered on the Lunar New Year, also known as the Spring Festival, which falls this year on Jan. 25. The period began Friday and runs through Feb. 18. “The emergence of the epidemic may cause panic among people, especially in areas where people are concentrated during the Spring Festival travel period,” the ministry’s chief engineer, Wang Yang, told reporters at a news conference Thursday. “In order to further ensure the health of passengers, our ministry attaches great importance to the arrangements and deployment, and will focus on the disinfection monitoring and protection measures in areas with a large number of passenger travel volume, including transportation hubs, passenger stations and cargo hub plant stations,” Wang said. Possible cases of the same illness have been reported in Hong Kong, South Korea and Taiwan involving recent travelers to Wuhan. Health authorities elsewhere in China have yet to announce similar cases, despite the high population density around Wuhan and its role as a travel hub for central China. University of Hong Kong disease expert Yuen Kwok-yung was quoted by the city’s official news agency as saying that the genetic makeup of the novel coronavirus was 80% similar to SARS as it had been found in bats, civet cats and humans. Yuen said that it was unclear whether the virus could further change to become more lethal, as the SARS virus had, but that Hong Kong had a robust system for detecting more severe problems among patients. “So we have to take every measure and closely monitor the situation,” Yuen said, according to Radio Television Hong Kong. Claim: China reports 1st death from new type of coronavirus .
Health authorities in a central Chinese city on Saturday reported the country’s first death from a new type of coronavirus, as the government braced for the Lunar New Year travel boom amid concerns over a possible outbreak similar to that of the SARS virus in the early 2000s.

Paragraph: "There is no mention of cost. The story could have at least reported what the drug costs in its current use against blood cancer. The story did a good job of explaining both the potential benefits and harms of the drugs. This was a particular strength of this story – and made it stand out in comparison with the LA Times blog story that we also reviewed. Harms were emphasized from the outset – even in the headline – in the AP story but were never mentioned in the LA Times story. And this story reminded readers of the side effects encountered with another MS drug, Tysabri. Outstanding job on this issue by the AP. The story did a very good job of explaining the studies. There is no sign of disease-mongering in this story. Two apparently independent sources were quoted. The story did a good job comparing the new drugs with existing approaches to treat MS. Story explains that the drug is already sold to treat a rare blood cancer and stated that ""it’s too soon to know if the pills will be approved by the government or widely adopted by physicians."" It does not report, however, as the LA TImes blog did, that ""The drug company MD Serono, an affiliate of Merck, has requested approval from the Food and Drug Administration to market the tablet. However it recently received a ""refuse to file"" letter from the FDA, which means the agency is requiring additional information or data. MD Serono said it is pursuing the matter with the FDA and hopes to re-submit its application."" We think that’s a crucial piece of information that affects availability, although, of course, doctors can still prescribe it for off-label use even before the FDA acts on the new request. The novelty of ""tests of the first two oral drugs developed for treating MS"" was clear in the story. It is clear that this story did not rely on a news release." Claim: MS pills show promise and risk, studies say
Nice job explaining harms and benefits – including putting the potential risks/harms right in the headline. The appeal of an oral drug for MS is clear. The risks emphasized in this story, though, raise important questions

Paragraph: This release notes several times that sestamibi SPECT/CT is inexpensive and widely available. It would have been good to include some cost estimates, particularly since reducing unneeded surgeries by the “thousands” presumably would be a huge cost savings. The release states that “The addition of sestamibi SPECT/CT increased the reviewers’ diagnostic certainty in 14 of the 48 patients, or in nearly 30 percent of all cases,” and that “Conventional imaging combined with sestamibi SPECT/CT had a value of 0.85, while conventional imaging alone had a value of 0.60.” The release offers that “a value of 0.50 indicates that a diagnostic test is no better than chance,” to give readers a benchmark for comparison. The release does address harms in terms of reduced harms from adding the imagining technology to standard diagnostic tests: “Even for patients whose tumors were not reclassified, the addition of sestamibi SPECT/CT increased physicians’ ability to more confidently classify malignant tumors, which reduces the risk of misdiagnosis and unnecessary surgery for all patients, the researchers say.” However, the potential harms from the test itself are not mentioned. Like CT, the test involves the use of ionizing radiation known to increase the risk of cancer. Though often minor, the contrast imaging agents (also called tracers or “dye”) injected prior to the test can cause allergic reactions, headaches, chest pain, dizziness, and other reactions. The release clearly states that the radiologists evaluating the imagery were unaware of the results of the surgery, that is, whether the tumors were cancerous or benign. It also states that “similarly ‘blinded’ pathologists analyzed the tumors without knowing the radiologists’ imaging results.”  This blinding of the researchers lends credibility to the findings even though the study itself involved a small number of participants. No evidence of disease mongering here. The release provides a good discussion of why more accurate imaging is needed for kidney tumor diagnosis. The release didn’t mention a funder. The release describes the results of comparing the diagnostic accuracy of regular CT or MRI scans alone or with the addition of sestamibi SPECT/CT imaging. The release also states that the alternative to diagnostic certainty is surgery, even when it is unknown whether the tumor is malignant or non-cancerous. The release notes in several places, including in the first sentence, that the technique is “widely available.” We know that to be true. The release states that radiologists at Johns Hopkins designed the approach of combining sestamibi SPECT/CT with CT or MRI to improve diagnostic accuracy in kidney tumors. Sestamibi SPECT/CT itself is not new. It is the standard imaging choice for assessing problems with the parathyroid glands, which are adjacent to the thyroid gland. The release does not rely on unjustifiable language. Claim: Noninvasive Imaging Test Shown Accurate in Ruling Out Kidney Cancers

This release from Johns Hopkins reports on a small, preliminary trial that shows adding a diagnostic imaging technique called sestamibi SPECT/CT to CT or MRI imaging tests led to more accurate diagnosis of kidney tumors, and subsequently, fewer unnecessary surgeries for benign tumors. Sestamibi SPECT/CT is short for 99mTc-sestamibi single-photon emission computed tomography/computed tomography. The release does many things very well, particularly in its discussion of the benefits of the technology and the study evidence. The release would have been even stronger with some more details of cost beyond saying it is inexpensive. Since the sestamibi SPECT/CT appeared to reduce the number of surgeries because of better tumor classification, it likely would be a huge cost savings to both patients and the health system. The ability to better classify tumors of the kidney and prevent unnecessary surgeries for benign tumors would be a boon for patients and the health care system. If these results hold in a planned larger study, the Johns Hopkins radiologists’ research could lead to wider adoption of sestamibi SPECT/CT and a significant reduction in unneeded surgeries.